Arben Ventures
Arben Ventures is an early-stage deep-tech health venture capital firm based in Palo Alto, California. Founded in 2023 by Stanford researchers Ariel Ganz and Ben Rolnik, the firm focuses on funding transformative healthcare innovations that are too advanced for academic support but still early for traditional venture capital. With a mission to accelerate technologies that improve health outcomes, Arben Ventures emphasizes areas such as precision medicine, multi-omics, early cancer detection, women’s health, mental health, and longevity. The firm has made significant strides in its investment
Investing activity
Arben Ventures appears in 1 AI deal tracked by the AI Lounge deals desk. The rounds are mostly Seed, with a median round size of $4M. The most recent is ChemT Biotechnology (Seed, $4M, Jun 2026).
Arben Ventures most often invests alongside Wavemaker Partners, Wavemaker 360, ain and Seeds Capital, and the companies it backs on AI Lounge are mostly in AI.
Deals
Frequently asked questions about Arben Ventures
What AI companies has Arben Ventures invested in?
Arben Ventures's AI investments include ChemT Biotechnology. The 1 round on AI Lounge are listed on this page with amounts, dates and co-investors.
Where is Arben Ventures based?
Arben Ventures is based in Palo Alto, California, United States.
What stage does Arben Ventures invest at?
In the rounds tracked on AI Lounge, Arben Ventures has invested at Seed, with a median round of $4M.
Who does Arben Ventures co-invest with?
Arben Ventures's most frequent co-investors on AI Lounge are Wavemaker Partners (1 deal), Wavemaker 360 (1 deal), ain (1 deal), Seeds Capital (1 deal) and Temasek Life Sciences Accelerator (1 deal).
How can founders reach Arben Ventures?
Founders on AI Lounge can see Arben Ventures's contact details in AI Investor Contacts (paid plans), check for a warm introduction through members who worked with the firm under Warm Paths, and add Arben Ventures to their Investor Pipeline to track the conversation.